US 12,447,158 B2
Liquid polymer delivery system for extended administration of drugs
John Milton Downing, Fort Collins, CO (US); Vipin Saxena, Carol Stream, IL (US); and John Middleton, Fort Collins, CO (US)
Assigned to Tolmar International Limited, Dublin (IE)
Filed by TOLMAR INTERNATIONAL LIMITED, Dublin (IS)
Filed on Aug. 9, 2023, as Appl. No. 18/446,687.
Application 18/446,687 is a continuation of application No. 16/995,020, filed on Aug. 17, 2020, granted, now 11,779,589.
Application 16/995,020 is a continuation of application No. 15/749,030, granted, now 10,786,515, issued on Sep. 29, 2020, previously published as PCT/US2016/045334, filed on Aug. 3, 2016.
Claims priority of provisional application 62/275,407, filed on Jan. 6, 2016.
Claims priority of provisional application 62/200,198, filed on Aug. 3, 2015.
Prior Publication US 2024/0066039 A1, Feb. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/568 (2006.01); A61K 9/00 (2006.01); A61K 38/09 (2006.01); A61K 38/29 (2006.01); A61K 47/34 (2017.01); A61K 47/59 (2017.01); A61P 5/26 (2006.01); A61K 38/00 (2006.01)
CPC A61K 31/568 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 38/09 (2013.01); A61K 38/29 (2013.01); A61K 47/34 (2013.01); A61K 47/593 (2017.08); A61P 5/26 (2018.01); A61K 38/00 (2013.01)] 19 Claims
 
1. A method for treating a disease in a subject in need thereof, comprising administering into the body of the subject an extended release pharmaceutical composition comprising:
a biodegradable liquid polyester having a carboxylic acid end group; a biocompatible organic solvent or combination of solvents; and
an active pharmaceutical agent,
wherein:
the extended release pharmaceutical composition is formulated to release the active pharmaceutical agent for a period of one month or greater;
the extended release pharmaceutical composition is free of a polyester without a carboxylic acid end group; and
the biodegradable liquid polyester comprises lactide residues and monomer residues selected from the group consisting of caprolactone, trimethylene carbonate, and combinations thereof.